ArticleJournal of tissue engineering and regenerative medicine2010
Characterization of a human fetal spinal cord stem cell line, NSI-566RSC, and its induction to functional motoneurons.
Article in Journal of tissue engineering and regenerative medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 90 citations in OpenAlex.
- Long-term safety and clinical outcomes from a single-site phase 1 study of neural stem cell transplantation for chronic cervical spinal cord injury.Stem cell reports · 2026Article
- Spinal segment-specific properties of neural stem cells contribute to the outcomes of spinal cord injury repair.Science China. Life sciences · 2026Article
- Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S.Molecular therapy. Nucleic acids · 2025Article
- Establishment of a Serum-Free Human iPSC-Derived Model of Peripheral Myelination.ACS biomaterials science & engineering · 2024Article
- Engineered human spinal cord-like tissues with dorsal and ventral neuronal progenitors for spinal cord injury repair in rats and monkeys.Bioactive materials · 2023Article
- An induced pluripotent stem cell-derived NMJ platform for study of the NGLY1-Congenital Disorder of Deglycosylation.Advanced therapeutics · 2022Article
- Motor neuron replacement therapy for amyotrophic lateral sclerosis.Neural regeneration research · 2022Review
- Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies.Advanced therapeutics · 2022Article
- A functional hiPSC-cortical neuron differentiation and maturation model and its application to neurological disorders.Stem cell reports · 2022Article
- Advances and Perspectives in Dental Pulp Stem Cell Based Neuroregeneration Therapies.International journal of molecular sciences · 2021Review
- A Human-Based Functional NMJ System for Personalized ALS Modeling and Drug Testing.Advanced therapeutics · 2020Article
- Neuromuscular disease modeling on a chip.Disease models & mechanisms · 2020Review
- Advances, Challenges, and Perspectives in Translational Stem Cell Therapy for Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2019Review
- Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials.Expert opinion on investigational drugs · 2019Review
- Regenerating Corticospinal Axons Innervate Phenotypically Appropriate Neurons within Neural Stem Cell Grafts.Cell reports · 2019Article
- Temporal Characterization of Neuronal Migration Behavior on Chemically Patterned Neuronal Circuits in a DefinedACS biomaterials science & engineering · 2018Article
- Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS.Annals of clinical and translational neurology · 2018Article
- Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics.Biomaterials · 2018Article
- Restorative effects of human neural stem cell grafts on the primate spinal cord.Nature medicine · 2018Article
- Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges.Advanced healthcare materials · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Specific neuronal subtypes, especially motoneurons (MNs), derived from human stem cells provide a significant therapeutic potential for spinal cord diseases, such as amyotrophic lateral sclerosis (ALS) and spinal cord injury. So far, in vitro, MNs have only been successfully induced from embryonic stem cells (hESC) and human fetal cortical progenitors. Although neural progenitors from spinal cord would be a likely source for generating MNs, there has been no study reporting successful in vitro differentiation of MNs from spinal cord progenitors. This study first characterized a polyclonal spinal cord stem cell line isolated from an 8 week-old fetus. Then a paradigm was introduced to successfully induce MNs from this cell line, which was demonstrated by immunostaining using the MN markers HB9, Islet1 and choline acetyl transferase (ChAT). The combination of HB9 and ChAT immunostainings indicated that approximately 20% of the cells were MNs after this induction protocol. The presence of other cell types in the differentiated culture was also analysed. Finally, the electrophysiological properties of these differentiated MNs were characterized to confirm their functional integrity. The majority of these MNs fired repetitive action potentials (APs), which is an indicator of functional maturation. The recordings of spontaneous excitatory postsynaptic currents (EPSCs) confirmed the formation of synapses onto these MNs. This study reports the first successful differentiation of MNs from human spinal cord stem cells in vitro, providing a novel approach for obtaining functional MNs when designing the therapeutic strategy for spinal cord diseases or injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.